Daxor Corp Wins Support from the National Institutes of Health (NIH) Catalyze Preclinical Services Program
Portfolio Pulse from Benzinga Newsdesk
Daxor Corporation (NASDAQ:DXR), a leader in blood volume measurement technology, has been accepted into the National Institutes of Health (NIH) Catalyze Preclinical Services Program. This program supports preclinical development, including studies and activities needed to meet regulatory requirements for therapeutic and device submissions. The effort will be done in collaboration with two nationally recognized contract research organizations, to support the continued development of Daxor's non-nuclear fluorescent blood volume analyzer (BVA) device.
October 04, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Daxor's acceptance into the NIH program could potentially boost its reputation and accelerate the development of its BVA device. This could lead to increased investor confidence and a potential rise in stock price.
Being accepted into the NIH program is a significant achievement for Daxor. It not only validates the company's technology but also provides support for its preclinical development. This could accelerate the development and approval of its BVA device, potentially leading to increased revenues and a rise in stock price. The news is highly relevant and important for DXR investors.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100